Cargando…

Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico

Healthcare-associated adverse events represent a heavy burden of symptoms for pediatric oncology patients. Their description allows knowing the safety and quality of the care processes in countries with limited resources. This study aimed to describe the incidence, types, severity, and preventabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Vázquez-Cornejo, Edmundo, Morales-Ríos, Olga, Hernández-Pliego, Gabriela, Cicero-Oneto, Carlo, Garduño-Espinosa, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947076/
https://www.ncbi.nlm.nih.gov/pubmed/35324939
http://dx.doi.org/10.1371/journal.pone.0265450
_version_ 1784674352927604736
author Vázquez-Cornejo, Edmundo
Morales-Ríos, Olga
Hernández-Pliego, Gabriela
Cicero-Oneto, Carlo
Garduño-Espinosa, Juan
author_facet Vázquez-Cornejo, Edmundo
Morales-Ríos, Olga
Hernández-Pliego, Gabriela
Cicero-Oneto, Carlo
Garduño-Espinosa, Juan
author_sort Vázquez-Cornejo, Edmundo
collection PubMed
description Healthcare-associated adverse events represent a heavy burden of symptoms for pediatric oncology patients. Their description allows knowing the safety and quality of the care processes in countries with limited resources. This study aimed to describe the incidence, types, severity, and preventability of adverse events occurring in pediatric patients with acute lymphoblastic leukemia during the induction phase in a tertiary care pediatric hospital in Mexico. This study analyzed a cohort based on medical records of between 2015 and 2017. Initially, information on patients and adverse events was collected; subsequently, two pediatric oncologist reviewers independently classified adverse events, severity and preventability. Agreement between reviewers was evaluated. Adverse events incidence rates were estimated by type, severity, and preventability. One-hundred and eighty-one pediatric patients pediatric patients with acute lymphoblastic leukemia were studied. An overall adverse events rate of 51.8 per 1000 patient-days was estimated, involving 81.2% of patients during induction. Most adverse events were severe or higher (52.6%). Infectious processes were the most common severe or higher adverse event (30.5%). The presence of adverse events caused 80.2% of hospital readmissions. Of the adverse events, 10.5% were considered preventable and 53.6% could be ameliorable in severity. Improving the safety and quality of the care processes of children with acute lymphoblastic leukemia is possible, and this should contribute to the mitigation and prevention of adverse events associated morbidity and mortality during the remission induction phase.
format Online
Article
Text
id pubmed-8947076
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-89470762022-03-25 Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico Vázquez-Cornejo, Edmundo Morales-Ríos, Olga Hernández-Pliego, Gabriela Cicero-Oneto, Carlo Garduño-Espinosa, Juan PLoS One Research Article Healthcare-associated adverse events represent a heavy burden of symptoms for pediatric oncology patients. Their description allows knowing the safety and quality of the care processes in countries with limited resources. This study aimed to describe the incidence, types, severity, and preventability of adverse events occurring in pediatric patients with acute lymphoblastic leukemia during the induction phase in a tertiary care pediatric hospital in Mexico. This study analyzed a cohort based on medical records of between 2015 and 2017. Initially, information on patients and adverse events was collected; subsequently, two pediatric oncologist reviewers independently classified adverse events, severity and preventability. Agreement between reviewers was evaluated. Adverse events incidence rates were estimated by type, severity, and preventability. One-hundred and eighty-one pediatric patients pediatric patients with acute lymphoblastic leukemia were studied. An overall adverse events rate of 51.8 per 1000 patient-days was estimated, involving 81.2% of patients during induction. Most adverse events were severe or higher (52.6%). Infectious processes were the most common severe or higher adverse event (30.5%). The presence of adverse events caused 80.2% of hospital readmissions. Of the adverse events, 10.5% were considered preventable and 53.6% could be ameliorable in severity. Improving the safety and quality of the care processes of children with acute lymphoblastic leukemia is possible, and this should contribute to the mitigation and prevention of adverse events associated morbidity and mortality during the remission induction phase. Public Library of Science 2022-03-24 /pmc/articles/PMC8947076/ /pubmed/35324939 http://dx.doi.org/10.1371/journal.pone.0265450 Text en © 2022 Vázquez-Cornejo et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Vázquez-Cornejo, Edmundo
Morales-Ríos, Olga
Hernández-Pliego, Gabriela
Cicero-Oneto, Carlo
Garduño-Espinosa, Juan
Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico
title Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico
title_full Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico
title_fullStr Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico
title_full_unstemmed Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico
title_short Incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in Mexico
title_sort incidence, severity, and preventability of adverse events during the induction of patients with acute lymphoblastic leukemia in a tertiary care pediatric hospital in mexico
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947076/
https://www.ncbi.nlm.nih.gov/pubmed/35324939
http://dx.doi.org/10.1371/journal.pone.0265450
work_keys_str_mv AT vazquezcornejoedmundo incidenceseverityandpreventabilityofadverseeventsduringtheinductionofpatientswithacutelymphoblasticleukemiainatertiarycarepediatrichospitalinmexico
AT moralesriosolga incidenceseverityandpreventabilityofadverseeventsduringtheinductionofpatientswithacutelymphoblasticleukemiainatertiarycarepediatrichospitalinmexico
AT hernandezpliegogabriela incidenceseverityandpreventabilityofadverseeventsduringtheinductionofpatientswithacutelymphoblasticleukemiainatertiarycarepediatrichospitalinmexico
AT ciceroonetocarlo incidenceseverityandpreventabilityofadverseeventsduringtheinductionofpatientswithacutelymphoblasticleukemiainatertiarycarepediatrichospitalinmexico
AT gardunoespinosajuan incidenceseverityandpreventabilityofadverseeventsduringtheinductionofpatientswithacutelymphoblasticleukemiainatertiarycarepediatrichospitalinmexico